Aminoglycosides

Mechanism of Action - Potent Protein Killers

• Class Members: Gentamicin, Tobramycin, Amikacin, Streptomycin, Neomycin.
• Action: Irreversibly bind to the 30S ribosomal subunit.
  • Blocks the initiation of protein synthesis.
  • Causes misreading of the mRNA template, leading to nonfunctional proteins.
  • Results in a potent, bactericidal effect.
• 📌 Mnemonic: "buy AT 30, CCEL at 50" (Aminoglycosides & Tetracyclines at 30S; Clindamycin, Chloramphenicol, Erythromycin, Linezolid at 50S).

⭐ Aminoglycosides exhibit concentration-dependent killing and a significant post-antibiotic effect (PAE), allowing for effective once-daily dosing regimens.

Spectrum & Uses - The Gram-Negative Busters

Potent bactericidal activity primarily against aerobic Gram-negative rods. They require $O_2$ for uptake, making them ineffective against anaerobes.

• Primary Targets: Pseudomonas aeruginosa, Klebsiella spp., E. coli.
• Synergistic Use: Combined with cell wall inhibitors (β-lactams, vancomycin) to broaden coverage or for a synergistic kill.
  • Gram-Positive: Treats serious infections like Enterococcal or Staphylococcal endocarditis.
  • Gram-Negative: Empiric therapy for sepsis.

⭐ Aminoglycosides are ineffective against anaerobes because their transport into the bacterial cell is an oxygen-dependent process.

Adverse Effects - Kidneys & Ears Beware

📌 Mnemonic: "Ami-NO" for Nephrotoxicity & Ototoxicity.

• Nephrotoxicity:
  • Causes acute tubular necrosis (ATN), leading to ↑ serum creatinine.
  • Damage is concentration-dependent and usually reversible upon discontinuation.
• Ototoxicity:
  • Causes irreversible damage to inner ear hair cells.
  • Auditory (cochlear) damage → tinnitus & hearing loss.
  • Vestibular damage → vertigo, ataxia.
• Neuromuscular Blockade:
  • Can induce muscle paralysis by inhibiting presynaptic acetylcholine release.
  • ⚠️ High risk in patients with Myasthenia Gravis or those receiving neuromuscular blockers.
• Therapeutic Drug Monitoring (TDM):
  • Monitor trough levels to prevent accumulation and dose-dependent toxicities.

⭐ Loop diuretics (e.g., furosemide) greatly potentiate the risk of aminoglycoside-induced ototoxicity.

Resistance Mechanisms - The Bacterial Defense

• Enzymatic Modification (Most Common): Bacterial transferase enzymes, often plasmid-mediated, inactivate the drug via:
  • Acetylation
  • Phosphorylation
  • Adenylation
• Impaired Entry: Reduced drug uptake due to porin channel mutations or altered transport systems.
• Altered Target: Mutations in the 30S ribosomal subunit binding site decrease drug affinity.

⭐ Amikacin is often effective against gentamicin and tobramycin-resistant strains as it is a poor substrate for many inactivating enzymes.

High‑Yield Points - ⚡ Biggest Takeaways

• Aminoglycosides are bactericidal inhibitors of the 30S ribosomal subunit, targeting serious aerobic gram-negative infections.
• Exhibit concentration-dependent killing and a significant post-antibiotic effect (PAE), allowing for once-daily dosing.
• Major dose-limiting toxicities are nephrotoxicity (reversible ATN) and irreversible ototoxicity (cochlear and vestibular).
• Can cause neuromuscular blockade, a key contraindication in Myasthenia Gravis.
• Used synergistically with cell wall agents (β-lactams) for certain gram-positive infections.